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Abstract
Background: In breast cancer, progesterone receptor (PR) positivity or abundance is positively associated with survival
and treatment response. It was initially believed that PR was a useful diagnostic marker of estrogen receptor activity,
but increasingly PR has been recognised to play an important biological role in breast homeostasis, carcinogenesis and
metastasis. Although PR expression is almost exclusively observed in estrogen receptor positive tumors, few studies
have investigated the cellular mechanisms of PR action in the context of ongoing estrogen signalling.
Methods: In this study, we contrast PR function in estrogen pretreated ZR-75-1 breast cancer cells with vehicle treated
ZR-75-1 and T-47D breast cancer cells using expression microarrays and chromatin immunoprecipitation-sequencing.
Results: Estrogen cotreatment caused a dramatic increase in the number of genes regulated by progesterone in
ZR-75-1 cells. In T-47D cells that have naturally high levels of PR, estrogen and progesterone cotreatment resulted in a
reduction in the number of regulated genes in comparison to treatment with either hormone alone. At a genome
level, estrogen pretreatment of ZR-75-1 cells led to a 10-fold increase in the number of PR DNA binding sites detected
using ChIP-sequencing. Time course assessment of progesterone regulated genes in the context of estrogen
pretreatment highlighted a series of important regulatory pathways, including those driven by epithelial growth factor
receptor (EGFR). Importantly, progesterone applied to cells pretreated with estradiol resulted in switching of
the PAM50-determined intrinsic breast cancer subtype from Luminal A to Basal-like, and increased the
Oncotype DX® Unscaled Recurrence Score.
Conclusion: Estrogen pretreatment of breast cancer cells increases PR steady state levels, resulting in an
unequivocal progesterone response that upregulates key members of growth factor pathways. The transformative
changes progesterone exerts on the breast cancer subtype suggest that these subtyping tools should be used with
caution in premenopausal women.
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Background
Breast cancer is the most commonly diagnosed invasive
cancer in females [1] and is most often an estrogen (17β-
estradiol) driven tumour [2, 3]. The primary cellular medi-
ator of estrogen is the intracellular transcription factor es-
trogen receptor alpha (ERα), which is expressed in 75 % of
early breast cancers [4]. ERα and PR positivity as assessed
via immunohistochemistry of primary breast cancer is cur-
rently the gold standard indicator for hormonal therapy,
applied either at the time of diagnosis or subsequent to
surgical, chemotherapeutic and/or radiation management.
While the molecular mechanisms and consequences of
estrogen-mediated action have received considerable re-
search attention, the molecular mechanisms of progester-
one signalling have not been as widely reported. More
recently PR is emerging as a key mediator of normal mam-
mary gland development and tumorigenesis in mice, pro-
moting mammary stem cell expansion and directing the
immune microenvironment [5–10].
The majority of the cellular effects of progesterone are
mediated by the progesterone receptor (PR), an intracel-
lular transcription factor of which two isoforms exist,
PR-A and PR-B. Because PR is an estrogen regulated
gene, the expression of PR protein detected by immuno-
histochemistry as a diagnostic tool was found to discrim-
inate between those most likely to respond to endocrine
therapy, from those that will not [11, 12]. Indeed, ex-
pression of PR in breast cancer in the absence of ERα is
rare (1.5 % of cases), and evidence suggests that such
cases may represent false negatives for ERα staining
upon re-analysis [13–16]. Nevertheless, PR appears to be
more than a mere diagnostic indicator of estrogenic ac-
tivity, as clinical studies have demonstrated it to be an
independent biomarker of endocrine therapy response as
well as a prognostic biomarker in postmenopausal breast
cancers [12, 16–18]. Smaller studies in premenopausal
women have found that tumours containing higher PR
positivity had the best response to tamoxifen [19].
In premenopausal women, the physiological role of pro-
gesterone is inextricably linked to that of estrogen, with
regards to production and secretion by the ovaries during
the menstrual cycle. Increased production of estrogen by
the maturing follicles ultimately results in ovulation, after
which the corpus luteum produces and secretes progester-
one. The secretion of progesterone in turn acts on the ad-
renal glands to stimulate a concomitant secondary, albeit
smaller, peak of serum estrogen [20]. Evidence also sug-
gests that the postmenopausal breast is capable of seques-
tering and/or synthesising progesterone and estrogen
from circulating hormonal precursors [21–25]. Collect-
ively, it appears most likely that PR is activated within a
hormonal milieu that includes active estrogen signalling.
Genomic and functional studies of receptor action in
vitro now provide unprecedented detail into the precise
mechanics of ERα and, to a lesser extent, PR action in
breast cancer cells. Those for PR have, however, been ex-
clusively performed in the absence of exogenous estro-
gen [26–31]. Binding of estrogen by ERα and
progesterone by PR results in association of the recep-
tors with specific sites on chromatin. Receptor binding
to DNA subsequently directs the recruitment of cofac-
tors and associated coactivators and corepressors, result-
ing in modification of the local chromatin landscape and
activation or repression of target genes. Indirect tether-
ing of the receptors to chromatin has also been observed
via interaction with DNA-bound factors such as AP-1,
Stat3 and SP1 [27, 32, 33]. Despite the findings that PR
expression is almost always accompanied by ERα expres-
sion [16], to date there are few reported studies investi-
gating progesterone transcriptional signalling and PR
binding in the context of estrogen-mediated signalling.
Indeed, most studies of PR DNA binding have been per-
formed in T-47D breast cancer cells that do not depend
upon estrogen for PR expression [34]. In this report, we
demonstrate a 10-fold induction in PR binding upon
progesterone treatment in estrogen pre-treated versus
non estrogen treated ZR-75-1 cells and demonstrate that
progesterone and estrogen cotreatment drive a unique
gene expression profile in ZR-75-1 that is distinct from
treatment with either hormone alone, which includes
up-regulation of signalling mediators of ErbB pathways.
Estrogen and progesterone cotreatment cause significant
changes to the predicted intrinsic breast cancer subtype,
specifically to one that resembles more aggressive, ther-
apy resistant disease.
Methods
Cell lines and culture
ZR-75-1, T-47D, MCF-7, MDA-MB-231, BT-20 and
MDA-MB-453 cells were obtained from the American
Type Culture Collection (Rockville, MD) and maintained
in RPMI 1640 (Life Technologies, NSW, Australia) con-
taining 10 % (ZR-75-1) or 5 % (T-47D, MCF-7) fetal
bovine serum (FBS) (Sigma-Aldrich, NSW, Australia).
All experiments were performed within 20 passages of
supply from ATCC (Manassas, Virginia).
Immunoblot analysis
ZR-75-1, T-47D, MCF-7, MDA-MB-231, BT-20 and
MDA-MB-453 cells were seeded in 6 well plates at
5 × 105 cells/well in phenol red free RPMI 1640
containing 5 to 10 % hormone stripped FBS (Sigma-
Aldrich), in the proportions indicated for each cell
type above. Hormone stripped treatment medium was
supplemented with 10nM estrogen where indicated.
After 72 h, medium was replaced with the indicated
hormone treatment for the specified time. Cells were
lysed, protein concentration assessed, electrophoresed
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and transferred to Hybond-C membrane as previously de-
scribed [31]. Membranes were probed using AR-N20, PR-
H190, ERα-HC20, CTSD-H75, FKBP5-H100 (Santa Cruz
Biotechnology, CA), calnexin (CANX, Thermo Scientific,
VIC, Australia), and anti-tubulin alpha (TUBA, Millipore,
VIC, Australia) and detected as previously described [31].
Microarray, RNA extraction and RT-qPCR
Cells were plated for 72 h in 6-well plates in phenol red-
free RPMI 1640 containing 10 % hormone stripped FBS
at 5 x 105/ well, treated for 16 h with vehicle (ethanol;
V.C), 10nM estrogen, 10 nM progesterone, 10 nM estro-
gen + 10nM progesterone, or for 72 h with 10nM estro-
gen (pretreated) with or without subsequent 10nM
progesterone for 4, 8 or 16 h. RNA was extracted using
RNeasy kit (Qiagen, VIC, Australia). The ZR-75-1 micro-
array results presented in Fig. 1 represent findings from
quadruplicate samples randomly hybridised to Illumina
HumanWG-6v3 chips (Australian Genome Research Fa-
cility, St Lucia, Australia). Raw transcript expression data
was exported from Illumina BeadStudio software and
analysed using the Bioconductor Limma package imple-
mented in R [35], as previously described [31]. Briefly,
we normalised array data using variance stabilisation
normalisation [36], corrected the data with Combat [37],
filtered to likely expressed transcripts (~24,000) and sub-
jected the data to linear model fitting. Regulation com-
pared to vehicle was accepted for an empirical Bayes
moderated t-statistic incorporating Benjamini-Hochberg
correction of ≤0.05. Microarrays in T-47D cells pre-
sented in Fig. 1 were performed in triplicate and were
hybridised to Illumina HumanWG-6v2 chips (Genomics
Core, Norris Comprehensive Cancer Centre, University
of Southern California, USA). Raw transcript expression
data was processed as described above, but subjected to
two Combat corrections due to array batch effects. Sam-
ples for the ZR-75-1 time course microarray presented
in Fig. 5 were generated in 5 × 105 cells per well in 6
well plates in triplicate from ZR-75-1 cells treated with
72 h 10nM estrogen or vehicle, followed by 4, 8 or 16 h
10nM progesterone treatment. Hormone treatments
were performed by overlaying the progesterone treat-
ment on the existing media and the experiment was per-
formed with reverse timing so all samples were collected
at the same time point. Triplicate RNA samples were
hybridised to human Gene 1.0 ST Affymetrix Arrays
(Adelaide Microarray Centre, Adelaide, Australia). Raw
CEL files were normalised, filtered for expressed tran-
scripts (~23,875) and subjected to linear model fitting.
Regulation compared to E2 pretreated samples was ac-
cepted for P4 treated samples for a Bayes moderated t-
statistic with Benjamini-Hochberg correction of ≤0.0001,
yielding a total of 2140 genes regulated at some point
over the whole time course. Validation for all microarray
results was performed on independent RNA samples by
RT-qPCR using iQ SYBR Green Supermix (BioRad Life
Science, NSW, Australia) on the CFX-96 PCR machine
(Bio-Rad). Primer sequences are provided in Additional
file 1. All microarray data is available online at NCBI
(accessions GSE61538, GSE61368 and GSE62243). Path-
way overrepresentation analysis was performed on dif-
ferentially expressed genes using the comprehensive,
publicly available InnateDB database, with hypergeo-
metric testing and Benjamini-Hochberg correction for
false discovery rates [38]. Clustering of microarray data
was performed using the K-means clustering method, with
20 random starts in STEM, and a maximum output set to
8 model profiles [39].
Cell cycle studies
ZR-75-1 cells were plated in 6 well plates in phenol red-
free RPMI 1640 containing 10 % hormone stripped FBS
and 10nM estrogen at 5 × 105/ well for 72 h. Cells were
then treated with 10nM progesterone or equivalent ve-
hicle for 24 h. Cells were washed in PBS, harvested and
fixed in ice cold 70 % ethanol. Fixed cells were incubated
in 50 μg/ml propidium iodide (Sigma Aldrich), 40 μg/ml
RNAse A (Life Technologies, NSW, Australia) and 0.1 %
Tween20 (Sigma Aldrich) in PBS for 2 h in the dark. Cell
cycle analysis was conducted on a FACSCanto II running
DIVA software (BD Bioscience, NSW, Australia). DNA
frequency histograms were obtained using FlowJo soft-
ware (Treestar, Oregon, USA) using the Dean-Jett-Fox
model. Results are representative of three independent
experiments.
Chromatin immunoprecipitation (ChIP) and ChIP-sequencing
ChIP and ChIP-sequencing was performed as previously
described [31]. Briefly, ZR-75-1 and T-47D cells were
plated for 72 h in phenol red-free RPMI 1640 containing
10 % hormone stripped FBS with 10nM estrogen or
equivalent vehicle. After 72 h, medium was supple-
mented with the indicated hormone for 4 h. Immuno-
precipitation was performed with PR-H190X or normal
rabbit IgG antisera (Santa Cruz Biotechnology, CA). In
total, 4 independent ChIP experiments were performed,
each independently validated by RT-qPCR at an enhan-
cer region of FKBP5 and a nonspecific DNA region.
Peaks were called and analysis was performed as de-
scribed in [31]. Briefly, Genomic regions with a peak
height of 3 (minimum of 3 independent 36 bp reads/site
on a Illumina Genome Analyser II) were recorded using
FindPeaks4 (Vancouver Short Read Analysis Package;
http://vancouvershortr.sourceforge.net/) on human gen-
ome build 18 (hg18) and subsequent analysis was per-
formed in R using custom algorithms as outlined in [31].
Bed files are provided as Additional files, and the pri-
mary data has been deposited at NCBI. Manipulation of
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Fig. 1 (See legend on next page.)
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intervals for analysing overlaps between different PR
ChIP-seq datasets was performed in R, Galaxy [40] or
BiSA [41]. The ChIP-seq datasets Conservation of binding
sites amongst vertebrates was performed using the Cis-
trome Analysis Pipeline (http://cistrome.dfci.harvard.edu/
ap). Regions of PR binding were annotated with respect to
neighbouring genes using ChIPpeakAnno [42] and Cis-
Genome [43]. High confidence sites were defined by our
ability to empirically validate selected PR binding sites in
independent samples (Additional file 2). To compare
strength of PR binding at specific peak subsets, sequence
tag libraries were generated and average tag density at the
subsets was determined using the peak annotation func-
tion in HOMER v4.2 [44]. Novel sequence motifs that
were present in PR binding regions statistically signifi-
cantly more frequently than expected by random chance
were identified using Gibbs Motif Sampling [45] or
MEME [46]. Known sequence motifs in the JASPAR
CORE vertebrata database [47] that were significantly
enriched in the PR cistrome were identified using CisGen-
ome, with default parameters [47, 48]. Fold enrichment
and significance (Fisher’s exact test) of motif sequences
were estimated compared with an equal number of 1-kb
control regions with matched physical distribution.
Results
Shaping of the progesterone response by estrogen in
breast cancer cells
To ascertain the most appropriate breast cancer cell line
model to investigate the physiological progesterone re-
sponse in the context of estrogen signalling, we assessed
alterations in steady state protein levels of ERα, PR, an-
drogen receptor (AR), Cathepsin D (CTSD) and FK506
binding protein 5 (FKBP5) in response to estrogen, pro-
gesterone and 5α-dihydrotestosterone (DHT) in a panel
of breast cancer cell lines. Of the cell lines tested, only
MCF7, T-47D and ZR-75-1 had detectable levels of both
ERα and PR upon immunoblotting (Fig. 1a and Additional
file 3). As the results in Fig. 1a were obtained with differ-
ent exposure times, depending on the steady state level of
the protein, we then compared the relative steady state
levels of ERα and PR in MCF7, T-47D and ZR-75-1 cells
and found that ZR-75-1 cells had the most equivalent de-
tectable expression of all three receptors (Fig. 1b). Upon
estrogen treatment, increased steady state levels of PR and
CTSD were most dramatic in ZR-75-1 and T-47D cells, in-
dicating activation of ERα. We observed that treatment of
the cell lines with progesterone resulted in increased steady
state levels of FKBP5 in T-47D cells but not in ZR-75-1
cells (Fig. 1a). This observation is not due to methodo-
logical artefacts as we were able to observe an increase in
FKBP5 in ZR-75-1 cells in response to the androgen
5alpha-dihydrotestosterone (DHT).
To examine the potential regulatory effects of proges-
terone in the presence and absence of estrogen signal-
ling, we performed microarray expression profiling of
ZR-75-1 and T-47D cells following treatment with ve-
hicle, estrogen, progesterone or both ligands in combin-
ation. Only 2 genes were regulated by progesterone
alone in ZR-75-1 cells (SERPINA3 and SEPT4; see
Additional file 4). In contrast to these results, we were
able to observe a small but consistent increase in FKBP5
expression upon RT-qPCR in ZR-75-1 cells in response
to progesterone treatment, which was not detected using
our cutoff criteria for differential expression on micro-
array (Fig. 1c; Benjamini-Hochberg corrected Bayesian
moderated t-statistic p < 0.05). In agreement, this small
increase in expression did not result in increased FKBP5
steady state levels upon progesterone treatment as ob-
served by immunoblotting (Fig. 1c versus Fig. 1a). In
contrast to the minimal effect of progesterone alone
in ZR-75-1 cells, cotreatment with estrogen and pro-
gesterone resulted in significant regulation of 216
genes (Benjamini-Hochberg corrected Bayesian moder-
ated t-statistic p < 0.05; Fig. 1c; see Additional file 4). Al-
though 170 of these genes were also regulated upon
estrogen treatment alone (78.7 %; Fig. 1c; see Additional
file 4), 46 (21.3 %) were unique to the progesterone and
estrogen cotreatment. In addition, cotreatment with pro-
gesterone resulted in the loss of regulation of 56 genes
(See figure on previous page.)
Fig. 1 Estrogen and progesterone induce a unique transcriptomic response in ZR-75-1 and T-47D cells. a Protein steady state levels of ERα, PR-A,
PR-B, androgen receptor (AR), androgen and progesterone regulated gene FKBP5 and estrogen regulated gene CTSD in ZR-75-1, T-47D and MCF-7 cells
treated with ethanol (v.c.), 10nM DHT, 10nM PROG or 10nM estrogen for 16 h. TUBA and calnexin (CANX) were utilised as controls. Note that exposure time
was different for each cell line and was optimised to visualise changes in response to hormone treatment. b Non hormone treated protein steady state
levels of ERα, PR-A and PR-B in ZR-75-1, T-47D and MCF-7 cells treated with v.c. for 16 h. Alpha tubulin (TUBA) was utilised as a control. Exposure times were
different from the blot presented in Fig. 1a. c Microarray analysis of the transcriptomic response of ZR-75-1 cells treated with ethanol (v.c.), 10 nM estrogen,
10 nM PROG, or cotreated with 10 nM estrogen and 10 nM PROG for 16 h. Euler diagram (left) demonstrates commonly regulated genes and
those uniquely regulated by the hormonal cotreatment. Histograms (right) demonstrate validation of progesterone-regulated responses in independent
samples. Expression presented relative to housekeeping gene GAPDH expression (d) Microarray analysis of the transcriptomic response of T-47D cells
treated with ethanol (v.c.), 10 nM estrogen, 10 nM PROG, or cotreated with 10 nM estrogen and 10 nM PROG for 16 h. Euler diagram (left) demonstrates
commonly regulated genes in response to each treatment. Histograms (right) demonstrate validation of progesterone-regulated responses in independent
samples. e Cell cycle analysis of propidium iodide stained ZR-75-1 cells after treatment for 24 h with vehicle (V.C; ethanol), 10nM progesterone or pretreated
for 72 h with 10nM estrogen (E2p), followed by 16 or 24 h of 10nM progesterone treatment (E2p + P4)
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(25 %) observed with estrogen treatment alone (Fig. 1c;
see Additional file 4). In T-47D cells in contrast, treatment
with progesterone alone resulted in regulation of 329
genes, of which 87 (26 %) were also significantly regulated
by estrogen alone (Fig. 1d; Additional file 5). Estrogen and
progesterone cotreatment resulted in the loss of regulation
of 24.9 % of estrogen responsive genes and 19.8 % of pro-
gesterone responsive genes. In contrast to ZR-75-1, only 3
genes were uniquely responsive to estrogen and progester-
one cotreatment in T-47D cells (GJB2, SSBP1 and ZFP36),
and far fewer were regulated upon estrogen and progester-
one cotreatment; 79 in T-47D, 216 in ZR-75-1 (Compare
Fig. 1c to d). Results using independent sets of RNA sam-
ples reflect those findings, with candidate genes (FKBP5,
THOC5, SERPINA3) showing significant upregulation in
response to estrogen and progesterone cotreatment in
ZR-75-1 cells, but no effect of estrogen and progesterone
cotreatment in T-47D on these candidates in comparison
to progesterone treatment alone (Fig. 1c). When the tran-
scriptomic profiles of ZR-75-1 cells cotreated with proges-
terone plus estrogen were compared with T-47D treated
with either progesterone only or estrogen plus progester-
one, only 9.8 % (21/214) and 11 % (25/214) of genes were
found to be in common. Collectively, these data indicate
that the cotreatment of ZR-75-1 cells with estrogen sensi-
tises the cells to progesterone and produces a unique tran-
scriptional response that is distinct from the response
mediated by estrogen or progesterone alone in either ZR-
75-1 or T-47D cells.
Pathway analysis was performed separately on proges-
terone upregulated and down regulated genes in T-47D
cells. Both of the gene lists were enriched for genes in-
volved in cell cycle. In the upregulated gene list, tran-
scriptional pathways were enriched, and pathways
involved in DNA synthesis were significantly enriched in
the downregulated gene list (see Additional file 6A and
B). In estrogen and progesterone cotreated T-47D cells,
fewer genes were regulated, but hormonal actions were
over represented, such as glucocorticoid receptor regula-
tion (see Additional file 6C and D). Enrichment of hor-
monal pathways was more evident in estrogen and
progesterone treated ZR-75-1 cells, along with enrich-
ment of genes involved in growth factor receptor signal-
ling (Additional file 7A and B). These results suggest
that estrogen and progesterone cotreatment in ZR-75-1
and T-47D cells produces a different transcriptomic re-
sponse from progesterone alone in either cell type.
Hence, the physiological effect of estrogen pretreatment
on ZR-75-1 responsiveness to progesterone was assessed
via cell cycle analysis using flow cytometry. Administra-
tion of progesterone to ZR-75-1 cells pretreated for 72 h
with estrogen resulted in an small increase in the pro-
portion of cells in the replicative S and G2M phases of
the cell cycle, and fewer in the quiescent G0-G1 phases
(Fig. 1e). This effect was not observed in cells treated
with progesterone only and is consistent with those pre-
viously observed in other breast cancer cell lines and
with the in vivo response in mice to estrogen and pro-
gesterone cotreatment [49, 50].
Estrogen pretreatment increases PR genomic occupancy
To characterise PR action in the context of estrogen
treatment, we performed PR ChIP-seq in ZR-75-1 cells
treated with progesterone alone or after estrogen pre-
treatment of the cells with 72 h of 10nM estrogen. DNA
pooled from 4 independently validated ChIP experi-
ments (Additional file 8) was subjected to next-
generation sequencing. After adjusting for input (see
methods), 49,927 progesterone alone and 75,030 estro-
gen pretreated + progesterone binding sites were scored.
Using these data, we identified 475 high confidence
binding sites in the progesterone alone PR cistrome and
4597 high confidence estrogen pretreated + progesterone
binding sites (Additional file 9; sites in .bed format).
Only 31 of those high confidence sites were shared be-
tween the two cistromes, and had a much greater aver-
age peak height in comparison to sites not shared
between the cistromes (Additional file 10A). Parallel
analysis in T-47D cells validated these as likely PR bind-
ing sites, but there was little evidence of increased en-
richment upon estrogen pretreatment (Additional file
10B). Western blotting revealed increased PR steady
state levels in ZR-75-1 cells following estrogen pretreat-
ment (Fig. 2a).
The estrogen pretreated and progesterone alone PR
binding sites are unique
Comparison of putative PR binding sites revealed a
much greater sequence conservation amongst verte-
brates for the progesterone treated, estrogen pretreated
binding sites than the binding sites identified after treat-
ment with progesterone alone, as well as a greater num-
ber of reads per peak (Fig. 2b-d). Using Gibbs Motif
Sampling and MEME analysis approaches, the most
highly enriched de novo motif in the estrogen pretreated
PR cistrome resembled canonical PR binding sites,
which were over-represented 3.24 and 3.69 respectively
in comparison to the background genome average
(Fig. 2e; p = <1 × 10−200, p = 1.49 × 10−184). Using these
same tools, we were unable to identify a recognisable de
novo hormone response element motif in the progester-
one alone cistrome, perhaps partly due to the small
number of sites interrogated. To identify factors that
may regulate the association of PR with chromatin, we
tested transcription factor binding motifs from the
JASPAR CORE vertebrata database for enrichment in
both PR cistromes (Additional file 11A and B). In the es-
trogen pretreated PR cistrome, the nine most highly
Need et al. BMC Cancer  (2015) 15:791 Page 6 of 17
enriched candidate motifs belonged to either steroid re-
ceptors or the forkhead family of transcription factors
(most notably, FOXA1). Also enriched were motifs for
transcriptional collaborators or tethering factors for ster-
oid receptors (AP-1, STAT3, RUNX1, C/EBP [51, 52]).
We also observed enrichment of binding sites for
Fig. 2 Estrogen pretreatment results in increased PR occupancy on DNA. a Steady state levels by immunoblotting of ERα, PR-A and PR-B in response
to 4 h of 10nM progesterone treatment alone or 72 h 10nM estrogen treatment followed by 4 h 10nM progesterone treatment. b Conservation in the
475 progesterone alone PR binding sites versus the 4597 estrogen pretreated, progesterone PR binding sites in ZR-75-1 cells. c Relative
strength of progesterone alone and estrogen pretreated, progesterone PR binding sites using peak annotation in HOMER. d The number
of reads per peak are centred around the middle of the binding sites in both data sets. e De novo analysis of the estrogenpprogesterone
PR dataset using both GIBBS and MEME revealed a PRE-like sequence as the most highly enriched motif. No PRE-like motif was found on
de novo analysis of the progesterone alone dataset. (f) Distribution of the binding sites relative to the nearest TSS reveal a similar distribution to that
of other studies [27, 29] and other receptors [31, 55]. g Binding sites were significantly enriched around the TSS of genes
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transcription factors implicated in cellular differentiation
(TEAD1, ZEB1; HAND1; C/EBPa, SPI1; ZNF354C), con-
sistent with a role for PR in this process in the breast
[8]. In comparison, the progesterone alone cistrome was
enriched for PR response elements, hormone response
element half sites and several binding sites for the Fork-
head (FOX) family. The transcriptional collaborators
GATA2 and NKX3.1, which have been reported as tran-
scriptional collaborators for PR and AR respectively
[53, 54], were also significantly enriched in the proges-
terone alone PR binding sites.
The estrogen pretreated, progesterone treated PR
binding sites were distributed predominantly in introns
and distal intergenic regions, with a moderate 13.24 %
found within 10 kb of transcriptional start sites (TSS;
Fig. 2f ). Nonetheless, these regions were enriched
around TSS in comparison to an equivalent number of
random genomic regions (Fig. 2g). This distribution is
similar to that reported by others for PR [27, 29] and for
other steroid receptors such as ERα and AR [28, 31, 55].
For our estrogen pretreated + progesterone PR binding
sites, 58-59 % overlap with two previously published PR
cistromes from T-47D cells, providing good support for
our empirically-based means of high confidence peak
threshold estimation (Fig. 3a; [27, 29]). De novo scanning
of the 2692 genomic regions shared between the 3 cis-
tromes using MEME revealed significant enrichment of
a motif that represents a canonical progesterone re-
sponse element (Fig. 3b; E-value = 8.3 × 10−41). More-
over, the sites shared between the 3 cistromes had a
significantly higher read density than those 1583 sites
unique to our set of estrogen pretreated + progesterone
PR binding sites (Fig. 3c). Together, these results suggest
a core set of PR binding sites conserved between differ-
ent breast cancer cell lines.
Upregulation of PR steady state levels by estrogen is the
primary mechanism of increased PR binding
As ERα and PR may interact on progesterone response
elements to mediate transcriptional activation [56], we
next assessed overlap between our previously published
ERα cistrome in ZR-75-1 cells [31] with the estrogen
pretreated PR cistrome generated here. Remarkably, that
analysis suggested only 5.2 % overlap between PR and
ERα binding sites in ZR-75-1 cells. Nevertheless, we did
identify enrichment of ERα binding sites around (within
10kB) the transcriptional start site of genes regulated by
estrogen and progesterone cotreatment in ZR-75-1 cells
(p = 1.42 × 10−27; Fig. 3e), and enrichment of both ERα
and PR binding sites near genes regulated by both
estrogen alone, and by estrogen and progesterone
cotreatment in these cells (p = 1.11 × 10−18; Fig. 3f ). To
elucidate, therefore, whether active ERα signalling is a
requirement for PR DNA binding, we performed candidate
PR ChIP in the presence of estrogen with or without
the ERα antagonist TAM. As expected, we found that
administration of TAM during estrogen pretreatment
(that preceding progesterone treatment) compromised
PR steady state levels and PR binding (Fig. 3g, h).
When cells were pretreated with estrogen alone and
then treated concurrently with TAM and progester-
one, there was no effect on steady state PR levels
(Fig. 3h), and only a small but consistent decrease in
PR binding at a number of sites. Athough active ERα
signalling may thus play a small role in strengthening
PR binding at some sites, the most likely mechanism
for the dramatic estrogen effect on the PR cistrome is
via an increase in cellular PR levels.
An important collaborator involved in both ERα and
PR DNA binding is FOXA1 [27, 55]. In this study, we
found a 40.6 % overlap between our estrogen pretreated,
progesterone treated PR binding sites and those previ-
ously published for FOXA1 in ZR-75-1 cells (Fig. 4a)
[55]. Moreover, within these overlapping sites there was
a strong concordance between peak centre and the loca-
tion of predicted FOXA1 and PR response elements
(Fig. 4b). This result reinforces the importance of
FOXA1 in PR DNA binding, specifically in the context
of estrogen treated cells.
The estrogen pretreated progesterone transcriptomic
response regulates growth factor signalling pathways
In order to comprehensively assess the transcriptional ef-
fects of progesterone in the context of active ERα signal-
ling, we performed whole genome microarrays on RNA
from estrogen pretreated ZR-75-1 cells subsequently
treated with or without 4, 8 or 16 h of 10nM progesterone.
As expected based on previous studies [57], the increased
PR steady state levels seen with estrogen pretreatment
were decreased following 16 h progesterone treatment
(Fig. 4c). We identified 2140 genes that were significantly
regulated over the progesterone time course in comparison
to estrogen pretreated cells (p < 0.0001; Additional file 12).
These results were validated on an independent RNA sam-
ple set (Additional file 13). Pathway analysis of this entire
gene set revealed significant enrichment of genes involved
in the EGFR pathway (NETPATH; p = 4.17 × 10−10), and in
intracellular and chemokine signalling pathways such as
MAPK and IL6 signalling (p = 0.008087 and p = 4.58 × 10−5,
respectively; Additional file 14). To determine the early ef-
fects of progesterone treatment, we next assessed pathway
enrichment for the 963 and 573 genes significantly up- or
down-regulated respectively after 4 h of progesterone
treatment. Both 4 h gene sets were significantly enriched
in genes involved in the EGFR1 pathway (p = 0.00032
and p = 0.000836; Additional file 15A and B). Fur-
thermore, we identified a significant overlap between
genes reported to be transcriptionally regulated by
Need et al. BMC Cancer  (2015) 15:791 Page 8 of 17
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EGFR (NETPATH ID#15908) and the entire 2140 estrogen
pretreated, progesterone regulated gene set (43/154
genes = 28 %; Fishers exact test: p = 1.412 × 10−13).
Significant upregulation of EGFR and EGF in response to
progesterone in estrogen-pretreated cells was confirmed by
RT-qPCR in an independent set of RNA samples (Fig. 4d),
which is in line with previously published observations [58].
To investigate the dynamics of progesterone transcrip-
tional regulation in estrogen-pretreated cells, we under-
took hierarchical clustering on the 2140 genes regulated
over the progesterone time course. For that analysis, we
reasoned there might be up to 8 general patterns, repre-
senting acute up or down regulation at one or more time
points, or more consistent regulation in the same direc-
tion. Of the 8 unsupervised clusters generated, the pat-
tern of regulation in Clusters 7 and 8 led us to collapse
them into Clusters 1 and 2 respectively. Overall, there
were two main trends of progesterone regulation. Acute
effects were observed in Clusters 3 and 5, where time-
dependent up or down regulation was observed followed
by a return to baseline by 16 h. The remaining 4 clusters
showed patterns of up or down regulation that were
maintained over the 16 h time course (Fig. 5a). Pathway
analysis of genes in Cluster 1 (chronically downregu-
lated) revealed enrichment in nuclear receptor and ster-
oid receptor regulation, and processes such as gland
development and ovulation cycle (Additional file 16A).
We reasoned that the downward pattern of regulation
might indicate estrogen upregulated genes antagonized
by co-treatment with progesterone. Indeed, 24.9 % (61/245)
of our identified estrogen regulated genes (shown in Fig. 1c)
were also found within Cluster 1. Cluster 2 genes, by con-
trast, were upregulated within 4 h of progesterone treat-
ment and sustained there over the 16 h time course. This
cluster was significantly enriched for genes involved in
EGFR signalling, and for phosphorylation and kinase ac-
tivity (Fig. 5a; Additional file 16B). Cluster 3 was acutely
down regulated and enriched for genes involved in the
EGFR1 pathway, as well as in cellular adhesion (Fig. 5a;
Additional file 16C). The stepwise upregulation of genes
in Cluster 4 represents enrichment of growth factor sig-
nalling (Fig. 5a; Additional file 16D), while acute upregula-
tion and return to baseline in Cluster 5 is overrepresented
by genes involved in Wnt and IL-6 signalling (Fig. 5a;
Additional file 16E). Cluster 6 represents late downregu-
lated genes, and is enriched for those involved in the
TGFβ signalling pathway (Fig. 5a; Additional file 16F).
Collectively, the above data identify progesterone, in
the context of continuous estrogen exposure, as a
regulator of a broad and unique transcriptional pro-
gram distinct from that by either hormone alone. In
the estrogen pretreated context, progesterone signal-
ling regulates a number of important signalling path-
ways in breast cancer, perhaps most notably the ErbB
signalling pathway.
Treatment with progesterone modulates the intrinsic
subtype status of estrogen pretreated breast cancer cells
To investigate further the impact of progesterone treat-
ment on estrogen pretreated breast cancer cells, we ap-
plied the two common expression-based breast cancer
phenotype tools, PAM50 and Oncotype DX® to our time-
course expression array data. Both tools have either ERα
signalling and/or growth factor receptor positivity at their
core [59, 60]. Indeed, 31/50 (62 %) genes in the PAM50 al-
gorithm [60] were significantly affected by progesterone
treatment in estrogen pretreated cells (Additional file 17).
Consistent with previous reports [61, 62], vehicle treated
ZR-75-1 cells exhibit a predominantly ‘Luminal A’ subtype
that was not altered in response to estrogen pretreatment
(Fig. 5b). However, treatment with progesterone at 4, 8
and 16 h after estrogen pretreatment altered expression to
such an extent that the closest PAM50 centroid changed
to ‘Normal’ at 4 h and ‘Basal-like’ at 8 and 16 h (Fig. 5b).
Assessment of the 21 gene algorithm contained within the
Oncotype DX® test [59] indicated that estrogen pretreat-
ment alone decreases the Unscaled Recurrence Score,
whereas the addition of progesterone treatment results in
(See figure on previous page.)
Fig. 3 Overlap of PR binding sites with other cistromes, and assessment of the involvement of ERα in PR binding. a Assessment of overlap of our
estrogen pretreated, progesterone PR binding site data with the more comprehensive Ballare and Clarke datasets [27, 29]. Clarke and our data was lifted
over to hg18 using UCSC tools, and overlaps were calculated using BiSA. b De novo analysis of the 1836 overlapping binding regions between our dataset
and those of Ballare and Graham reveals significant enrichment of a canonical HRE in these sites. c Comparison of the reads per peak between sites shared
between all 3 data sets and the remaining 2761 sites reveal more reads per peak in the shared sites. d Alignment of binding sites shared between our
previously published ERα binding sites and our estrogen pretreated, progesterone PR binding sites reveals close alignment between the centre of the
binding sites. e, f Assessment of overlap (within 10 kb) between our estrogen pretreated progesterone treated PR binding sites and our previously
published ERα binding sites and genes regulated by progesterone in estrogen pretreated cells. Numbers above each bar on the histograms represents
the p value from Fishers exact test of the regions compared to an equal number of 1 kb control regions across the genome. g ZR-75-1 cells (1.2 × 107 in
150 mm plates) were treated with vehicle or 10 nM estrogen for 72 h (pretreated; p) with or without 1 μM of the ERα specific antagonist Tamoxifen (TAM)
and subsequently treated for 4 h with progesterone with or without 10 μM TAM. ChIP assays were performed using anti-PR and anti-IgG antibodies, and
enrichment of the FKBP51 enhancer and nonspecific binding regions assessed by RT-qPCR. Data is representative of 2 repeated experiments, with the y
axis representing the Normalised percent input to a nonspecific control region. h Steady state levels by immunoblotting with PR, ERα and loading control
GAPDH of ZR-75-1 cells treated as described above in E
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a significant, time dependent increase in the Unscaled
Recurrence Score (p < 0.0001; Fig. 5c).
Discussion
In a recent meta-analysis, breast tumour subtyping via
the Oncotype DX® platform was found to guide clinical
decision making regarding the use of adjuvant chemo-
therapy in 34 % of early breast cancer cases [63, 64].
Moreover, the St Gallen International Expert Consensus
found that microarray-based intrinsic subtype classifica-
tion of breast cancers is an important guide for chemo-
therapy use in ERα positive, HER-2 negative disease
[65]. That panel did however recognise the potential
prohibitive cost of wide-spread multigene expression
analysis, and instead propositioned immunohistochemi-
cal surrogates such as dichotomising ERα positive breast
cancer cases on the basis of PR and Ki67 positivity
thresholds and HER2 status, even though such measures
have been found to be less accurate [17, 60, 65]. Despite
increased recognition and utility of subtype classification
in the clinical setting, the factors or conditions that
drive individual tumours into classifiable subtypes are
currently unknown. Even though this study was con-
ducted in breast cancer cell lines, the findings of this
study suggest that exposure to hormones may alter
the transcript profile of breast cancer cells sufficiently
to change their classification by multi-gene algorithms.
Specifically, we found that estrogen pretreated breast can-
cer cells exhibit a Luminal A subtype, which switches to a
Basal-like subtype upon combined estrogen and proges-
terone treatment. In support of steroid-induced effects on
intrinsic subtypes, the incidence of Basal-like tumours de-
creases significantly with age, from 44 % in premenopausal
aged patients (21–39 years) to just 9 % in patients aged
70–93, who exhibit lower, more static serum levels of pro-
gesterone and estrogen [66]. Indeed, the expression of PR
and other key estrogen regulated genes in breast tissue
from postmenopausal women is positively associated with
serum estrogen levels [67]. In the pre-menopausal setting,
a study of estrogen regulated genes throughout the men-
strual cycle in early breast cancer samples demonstrated a
significant increase in PR transcript and protein levels
during follicular and luteal phases (days 7–26), corre-
sponding with higher known circulating estrogens [68].
Fig. 4 Peak-centred binding in sites shared by our PR and FOXA1 and upregulation of EGFR and EGF upon estrogen and progesterone treatment.
a Overlap of FOXA1 binding sites identified in ZR-75-1 cells by Hurtado et al., with our estrogen pretreated, progesterone treated PR binding sites and
our previously identified ERα binding sites. b Alignment of our estrogen pretreated, progesterone treated binding sites with the ZR-75-1 FOXA1 binding
sites identified by Hurtado et al. [25]. c Steady state levels by immunoblotting of PR-A, PR-B, ERα and loading control GAPDH after 16 h 10nM progesterone
or estrogen and progesterone treatment, with or without 72 h 10nM estrogen pretreatment (E2p). d Validation of up regulation of EGFR and EGF upon
72 h 10nM estrogen pretreatment followed by increasing times of incubation with 10nM progesterone in independently prepared RNA samples
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Likewise, the expression of PR, a PR regulated gene
RANKL, and an ERα regulated gene, TFF1 are all signifi-
cantly higher in premenopausal in comparison to post-
menopausal women [69]. Recent studies demonstrate
intra-individual variability in multigene signature scores
between fine needle biopsies and resection specimens
[70]. Finally, PR abundance may decrease upon activation
by progesterone treatment, adding to the complexity of
using PR abundance as a surrogate for intrinsic subtype
status [57]. While the study reported herein is provocative,
these findings require careful validation in premenopausal
breast cancer patients. In the meantime, these data sug-
gest that careful consideration be given to the menopausal
status of women, and the concentration of circulating
Fig. 5 Assessment of the estrogen pretreated progesterone transcriptome reveals functionally associated clusters, and results in the ZR-75-1 cells
switching from a Luminal A to a Basal subtype. a Cluster analysis reveals 6 functionally associated clusters. b PAM50 analysis utilising the microarray
data using ZR-75-1 cells treated with 10nM estrogen for 72 h followed by vehicle treatment for 16 h (E2p + VC), or with 4, 8 or 16 h of 10nM progesterone
treatment. Colours represent the closest centroid for each sample type. c Unscaled recurrence score (uRS) from Oncotype DX™ calculated from microarray
data using the method described in [59]
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estrogen and progesterone at the time of tumour collec-
tion, if RNA-based subtyping tools, and perhaps their im-
munohistochemical surrogates are to be used in clinical
decision making.
The potential for plasticity between the intrinsic sub-
types of breast cancer has not been widely investigated.
From a clinicopathological perspective, nearly 70 % of
Basal-like tumours and just 3 % of Luminal A tumours
have a triple negative phenotype (ERα and PR negative
and no HER2/neu overexpression) [71], and 65 % of ERα
negative/PR positive tumours exhibit a Basal-like
PAM50 subtype [63–65]. Furthermore, tumours arising
in younger women have significantly lower ERα and PR
expression, but higher HER-2 and EGFR expression [72],
and in Basal-like breast cancers and breast tumours in
younger women, the level and expression of EGFR is an
adverse prognostic factor [72, 73]. While the studies
contained herein are preclinical in nature, we describe
that combinatorial estrogen and progesterone treatment
result in upregulation of several key members of the
EGFR signalling pathway. If this relationship is verified
in premenopausal and postmenopausal breast cancers, it
is possible that subtyping tools developed predominantly
from postmenopausal women may be particularly prone
to menstrual cycle-induced plasticity or hormone-driven
artefacts.
In ERα positive breast cancers, PR positivity is indica-
tive of a more favourable response to endocrine therapy
[16], but does not distinguish between a clinical re-
sponse to tamoxifen or aromatase inhibitors [18, 74].
Nonetheless, the percent and intensity of breast cancer
cells positive for PR protein by immunohistochemistry is
positively correlated with time to recurrence in both
tamoxifen and anastrozole treated patients, and Luminal
A type breast cancers containing more than 20 % PR
positive cells have a better prognosis than those with less
than 20 %, independent of endocrine therapy [59]. Thus,
while abundance of PR provides prognostic information
beyond ERα positivity, the important question is
whether this derives from the intrinsic biological activity
of PR, or is purely due to PR acting as a marker of the
extent of tumour cell ERα activity or responsiveness.
The intrinsic biological role of PR has been difficult to
study in breast cancers precisely because of its dependent
relationship on ERα, and the concordance between levels
of ERα and PR in breast cancers [12, 34, 75]. We show
here that PR action is dependent on the hormonal con-
text, with concurrent estrogen treatment producing a
unique transcriptomic response to progesterone. Com-
bined with our finding that the master regulator of a pro-
gesterone response in breast cancer cells appears to be
estrogen, which regulates PR abundance, thereby permit-
ting PR DNA binding, our findings suggest that the ac-
tions of estrogen and progesterone are inextricably linked.
Interestingly, the ancestral vertebrate steroid receptor was
a receptor that preferentially bound estrogens, with the
progesterone receptor the second steroid receptor to
evolve [76, 77]. Hence, the estrogen and progesterone re-
ceptors have the longest coexistence in relation to the
other steroid receptors, so perhaps it is not surprising that
a complex functional regulatory relationship exists be-
tween them, where ERα-mediated upregulation of PR
abundance permits activity in response to progesterone,
and PR in turn, regulates a subset of ERα actions [78, 79].
Mechanistically, we anticipate that a large part of the
unique response observed here is the sensitization to pro-
gesterone mediated by upregulation of PR by estrogen,
resulting in a combined estrogenic/progestogenic re-
sponse. Given that we observed a large overlap in binding
sites between ZR-75-1 cells cotreated with estrogen and
progesterone and those previously reported in T-47D cells
treated solely with progesterone, alternative binding of the
PR induced by estrogen treatment is unlikely to be the
sole cause of the unique estrogen and progesterone tran-
scriptome observed here. One possibility is that estrogen
treatment may cause differential regulation of transcrip-
tional collaborators, such as FOXA1. While further stud-
ies will determine the precise mechanism, we propose that
the counter-regulation of approximately one quarter of es-
trogen responsive genes upon progesterone treatment,
and upregulation of growth factor receptor pathways, may
together contribute to the unique transcriptome observed
here.
HER2 and/or EGFR overexpression is a cause of endo-
crine resistance, and ER positivity has been shown to de-
crease the effectiveness of HER2 targeting agents and
provide a potential avenue for resistance to HER2-
targeted therapies [55, 80–86]. Many molecular and clin-
ical studies suggest that HER2 and hormone receptor
positive breast cancers have the ability to switch between
hormonal-driven and ErbB-driven signalling, with this
switch mediating therapeutic resistance. This suggests
that each of these two pathways are sufficient to propa-
gate cancer cell growth, with the mechanistic switch
perhaps partly being explained in terms of estrogen-ERα
complexes or tamoxifen-ERα complexes repressing HER2
transcription [55]. Here, our data suggest that PR
may collaborate in the relationship or interplay be-
tween hormonal and ErbB signalling. While only in a
single breast cancer cell line, we demonstrate the po-
tential for progesterone to activate EGFR signalling,
consistent with progesterone potentiation of EGF re-
sponses in ZR-75-1 cells [48]. In early breast cancers
moreover, those carrying a gene signature represent-
ing activity of hyperphosphorylated PR were found to
have higher prevalence of HER2 positivity and distal
metastasis [60]. Together, these findings firmly pos-
ition PR as much more than a marker of ERα action
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in breast cancer, and our observations that both estro-
gen and progesterone play a role in the upregulation of
growth factor receptor pathways suggest that PR targeting
should be considered more closely as a partner in cur-
rently employed endocrine and ErbB-targeted therapies.
Conclusions
We demonstrate hormone-induced plasticity of subtype
status in breast cancer cells, confounding the notion of
an inherent intrinsic subtype. This is pertinent given the
expanding role of subtyping tools in the clinical setting,
and these results are particularly relevant for the use of
these subtypes or their surrogates in premenopausal
women. In addition, our data suggests that PR may act
as a mediator between ErbB-driven and hormonal-
driven cancer cell growth, and could represent a mech-
anism of hormonal treatment resistance that could be
targeted using currently available therapies.
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